重组腺病毒介导人肝细胞生长因子在病理性瘢痕基因治疗研究中的应用

采用细胞内质粒DNA同源重组方法, 将人肝细胞生长因子基因构建于E1, E3区缺失的复制缺陷型5型腺病毒载体上, 获得携带人肝细胞生长因子基因(HGF)的重组腺病毒Ad-HGF. 在293细胞中扩增后用氯化铯密度梯度离心法扩增制备Ad-HGF和Ad-GFP(携带绿色荧光蛋白报告基因的重组腺病毒), 然后, 用Ad-GFP和Ad-HGF体外分别转染原代培养的兔耳瘢痕成纤维细胞, 观察体外转染效率及表达, 并以新西兰兔耳瘢痕为体内模型, 观察局部瘢痕组织中一次性注射Ad-HGF后对已形成瘢痕的治疗作用. 结果显示: (ⅰ) Ad-GFP感染原代培养兔瘢痕成纤维细胞后, 3 d时转染效率为(36.8 ± 14.1)%, 并持续表达20 d以上. (ⅱ) 用ELISA方法检测Ad-HGF感染原代培养兔瘢痕成纤维细胞后HGF的表达, 结果感染后3 d表达量约为76 ng/4.0 ´ 105细胞. (ⅲ)用兔耳瘢痕模型观察在瘢痕内注射不同剂量(8.6 ´ 10⁹, 8.6 ´ 10⁸, 8.6 ´ 10⁷, 8.6 ´ 10⁶ pfu)的Ad-HGF, 于注射后第32天肉眼可见Ad-HGF治疗组瘢痕较治疗前明显缩小、变薄, 甚至与周围皮肤在同一水平. 这一效应呈剂量依赖性: 大、中剂量组(8.6 ´ 10⁹, 8.6 ´ 10⁸ pfu)治疗前后瘢痕肥大指数的减少有统计学意义(P<0.05), 尚可见不同程度再生的丛状新生毛, 低剂量组(8.6 ´ 10⁷, 8.6 ´ 10⁶ pfu)治疗后瘢痕肥大指数有减小但无统计学意义, 对照组多数瘢痕大小无明显变化. 光学显微镜观察组织切片显示, 治疗组真皮中纤维组织明显少于对照组, 并可见毛囊及皮脂腺的存在; 天狼猩红染色显示大剂量组创口中胶原纤维薄且稀少, 而低剂量组和对照组创口中仍有丰富的大而粗的Ⅰ型胶原. (ⅳ)治疗兔体内未检测到抗HGF抗体的存在. (ⅴ) 局部应用Ad-HGF所介导的基因只在局部表达, 不累及远隔的器官和组织, 也未见任何毒副作用. 结果提示, 以腺病毒介导人肝细胞生长因子基因治疗病理性瘢痕在整形外科中具有一定的应用前景.     

Gene therapy for pathological scar with hepatocyte growth factor mediated by recombinant adenovirus vector

Pathologic scar, characterized by excessive dermal fibrosis and scarring, is a common im-portant clinical sequela after wound healing. It often appears during wound healing after deep burn, surgical cutting and other injured skin. Accumulation of extracellular matrix (ECM) proteins is a manifestation of increased collagen synthesis and/or reduced matrix degradation, resulting in excessive scarring with a deformed appearance and dysfunction[1]. To date, treatment modalities to scar include sur…     

重组腺病毒Ad-HGF体外感染成纤维细胞后转染效率及表达的检测

押检测携带人肝细胞生长因子基因的重组腺病毒Ad-HGF在体外对成纤维细胞的感染效率以及感染细胞对目的蛋白的表达。以不同感染复数(m.o.i.)(25,50,100,200)的Ad-GFP感染NIH3T3细胞,48h时用流式细胞仪检测转染效率;以50m.o.i.感染NIH3T3细胞后48h,用ELISA和Western印迹杂交法分别检测感染上清中HGF的表达。分别以50m.o.i.的Ad-GFP和Ad-HGF感染原代培养人瘢痕成纤维细胞,以检测重组腺病毒对原代培养人瘢痕成纤维细胞的转染效率和其对HGF的表达。结果表明,当m.o.i.为50时,重组腺病毒对NIH3T3细胞的转染效率已达95%以上;HGF的表达量可达每2×106细胞249ng;并可检测到HGF蛋白的一特异杂交带。以50m.o.i.的Ad-GFP感染原代培养人瘢痕成纤维细胞,72h时GFP表达达高峰,此时转染效率可高达36.75%。Ad-HGF感染原代培养人瘢痕成纤维细胞后HGF的表达在72h时达高峰,表达量可达每3.3×105细胞66ng。初步认为重组腺病毒可有效地介导HGF基因转染正常或瘢痕成纤维细胞,且感染细胞可有效表达目的蛋白。     

重组腺病毒介导人野生型p53和B7-1基因诱导喉癌细胞凋亡并增强其免疫原性

为开展喉癌的复合基因治疗,观察共表达人野生型p53和B7-1基因的重组腺病毒Ad-p53/B7-1对喉癌细胞增殖及免疫原性的影响,检测到Ad-p53/B7-1介导的人野生型p53基因可抑制喉癌细胞增殖并诱导其凋亡,同时B7-1基因的导入可增强喉癌细胞的免疫原性基因修饰的癌细胞可刺激自体肿瘤浸润淋巴细胞增殖,并诱导外周血淋巴细胞形成对肿瘤具有特异杀伤性的细胞毒性T淋巴细胞。     

共表达人p53、GM-CSF和B7-1基因的重组腺病毒的构建

 为开展肿瘤的复合基因治疗 ,构建以串联方式携带人野生型p53、GM CSF和B7 1基因的重组腺病毒穿梭质粒pBB 1 0 2 .将pBB 1 0 2与腺病毒包装质粒GT40 50共转染 2 93细胞 ,通过细胞内同源重组获得重组腺病毒BB 1 0 2 .在 2 93细胞中扩增病毒 ,并通过氯化铯密度梯度超速离心纯化病毒 ,获得高滴度和高纯度的病毒 .分别经免疫组织化学分析、ELISA和流式细胞分析 ,检测BB 1 0 2介导的人野生型p53、GM CSF和B7 1基因在喉癌细胞Hep 2中的表达 .结果表明 ,BB 1 0 2能够有效地将其所携带的目的基因导入Hep 2细胞并使其在细胞中高效表达 ,表达高峰期为转染后 2～ 4d ,此后随时间递减 ,可持续 1 0d以上 .     

重组质粒pUDKH的质量分析

目的:分析研究pUDKH的质量。pUDKH是由本实验室构建的携带人肝细胞生长因子(HGF)基因的真核表达质粒,具有治疗肢体动脉闭塞病的应用潜能。方法:用光密度法分析pUDKH的浓度及纯度;用0.8%琼脂糖凝胶电泳分析超螺旋pUDKH比例及RNA;以地高辛标记的核酸探针固相斑点杂交法测定残留宿主DNA含量;用酶联免疫法测定残留宿主菌蛋白;以4组限制性内切酶分析一致性;PCR扩增目的基因片段;抑菌圈测定板测定残余抗生素;用鲎试剂检测细菌内毒素;对CHO细胞进行基因转染;ELISA检测上清HGF表达量;用Transwells法分析表达的上清液诱导ECV304细胞迁移数。结果:03批次pUDKH的浓度为1.97mg/mL,D260nm/D280nm值为1.84,超螺旋pUDKH比例为95.5%;电泳图谱中未见RNA;残留宿主DNA含量低于质粒DNA的0.2%;菌体蛋白质残留含量低于质粒DNA的0.1%;限制性酶切图谱与自行制备的对照品一致;PCR扩增到HGF基因片段,长约2.2kb;未见残余抗生素(卡那霉素)抑菌圈;细菌内毒素≤0.03125EU/mL;转染的CHO细胞上清HGF表达量为39.32ng/mL;表达的上清诱导ECV304细胞迁移数高于对照组2倍。结论:03批次pUDKH的质量符合药学规格。     

Gene therapy for pathological scar with hepatocyte growth factor mediated by recombinant adenovirus vector

A complementary DNA (cDNA) encoding human hepatocyte growth factor was introduced into a replication-defective type 5 adenovirus (lacking E1, E3 domains) vector by homologous recombination of intracellular plasmid DNA, thus a recombinant vector containing HGF (Ad-HGF) was obtained. Ad-HGF and Ad-GFP (adenovirus vector carrying green fluorescence protein gene) were expanded in 293 cells and purified by cesium chloride gradient centrifugation for large-scale preparation, then were infected to the primarily cultured scar fibroblast of rabbit ear to observe the transfer efficiency and expression level of HGF in vitro. To evaluate the effect of Ad-HGF on established scar Ad-HGF solution was injected into excessively formed scar, which bears some clinical and histologic similarities to human hypertrophic scars. The results showed that: (i) the transfer efficiency was 36.8% ±14.1% on day 3 in primarily cultured scar fibroblasts treated with Ad-GFP and lasted more than 20 d; (ii) high-level expression of HGF protein was detected by means of ELISA in supernatant of scar fibroblasts treated with Ad-HGF, the amount of expression was 76 ng/4.0 x 10⁵ cells on day 3; (iii) on day 32 after a single intradermal injection of Ad-HGF at different doses (8.6 x 10⁹ pfu, 8.6 x 10⁸ pfu, 8.6 x 10⁷ pfu, 8.6 x 10⁶ pfu) per scar, most of the scars in the former two dose groups were dramatically flattened, some were even similar to that of the normal skin. The value of Hl (hypertrophie index) showed that there was a therapeutic effect of Ad-HGF on scars at the dose of 10⁹ pfu and 10⁸ pfu. Whereas no therapeutic effects were seen at lower dose (10⁷ pfu and 10⁶ pfu of Ad-HGF) groups. In addition, clusters of hair were observed to different extent on healed wound treated with Ad-HGF. Histopathologic examination revealed that in most healed wounds of Ad-HGF treated group, the dermal layer was thinner, the amount of fibrous tissue was much fewer, and hair follicles growth and sebaceous glands were observed. In Sirius red-stained sections the amount of type I collagen in the Ad-HGF-treated scars was diminished markedly, compared to that in Ad-GFP group, in which a huge amount of type I collagen was still observed; (iv) immune response against HGF was absent. Antibody against HGF was not detectable by ELISA in serum from rabbit treated with Ad-HGF; (v) no local or systemic side-effects and toxicity associated with the gene transfer were found. These results demonstrated the potential use of treating pathologic scar by Ad-HGF, an alterative strategy of gene therapy for scar in clinical practice.     

人胎肝基质细胞培养上清液中造血生长因子的分析

采用人胎肝造血基质细胞的体外液体培养技术,结合造血干细胞和祖细胞的体外测试方法,研究了造血基质细胞所释放的造血生长因子与造血干细胞和祖细胞之间的相互作用。结果表明,在适宜的条件下,人胎肝造血基质细胞可在体外传代培养达100d之久。培养过程中,对不同时间收集的培养上清液进行测试的结果表明,这些贴壁细胞可以不断地释放多种造血活性物质。在100d培养过程中,上清液中始终都可以检出CFU-S增殖刺激物活性。培养第24天的上清液中还可检出BPF和GM-CSF活性。这些造血活性物质对CFU-S的生理状态和祖细胞的增殖与分化有着深刻的影响。但是在培养上清液中未检出IL-3样活性物质。     

新生牛肝脏生长因子的纯化及其理化特性与生物活性

新生牛肝细胞生长因子是一种热稳定、蛋白酶及酸化(pH<1.5)敏感的蛋白质或多肽。研究结果表明,它可促进肝来源的细胞系的DNA合成,但不能刺激非肝来源细胞系的DNA合成。它还可提高某些化合物(CCl_4,D-Gal)引起的急性肝衰竭小鼠的存活率。     

抗T细胞单克隆抗体(211－1)清除骨髓中T细胞的实验研究

本文报告应用抗T淋巴细胞单克隆抗体(211—1)和幼兔补体,体外处理骨髓细胞对GM－cFuc生成率无不良影响,并能清除骨髓中98％以上的T细胞。淋巴细胞转化试验也证明,211—1单克隆抗体可以清除骨髓中T细胞。